RocRock was selected as the national "unveiling list" technical research project

The only selected CAR-M enterprise in Suzhou

Professor Yin Xiushan's project "Macrophage Drugs Targeting Solid Tumors" was indeed listed as an innovative project in the "2023 National Biopharmaceutical Technology Innovation Center's Cell Therapy 'Top-Down Challenge' Technical R&D Project" on December 8, 2023. The project was submitted by RocRock Biotechnology (Suzhou) Co., Ltd., with Professor Yin Xiushan serving as the project leader.

As the first company in China with a macrophage engineering technology platform driven by gene editing, biomaterials, and synthetic biology, RocRock Biotech has been dedicated to promoting innovation and development in the field of life sciences. The company has pioneered the creation of a globally unique closed-loop industrial chain centered around macrophages. The research and innovation of the new generation of cell therapy technologies with macrophages at the core not only align with the country's strategic development requirements but also have significant innovative implications for achieving independent control over medical and pharmaceutical technology and enhancing the country's biopharmaceutical innovation capabilities. Kunshi's unique scientific concepts and cutting-edge technologies have successfully garnered high attention and recognition from the National Biopharmaceutical Technology Innovation Center.

Professor Yin Xiushan stated, "We are very honored to be part of the National Biopharmaceutical Technology Innovation Center's cell therapy project. This recognition is not only a testament to our team's achievements in the field of cell therapy over the years but also an encouragement for our commitment to advancing breakthroughs in solid tumor treatment."